ClinicalTrials.gg
CompletedNCT06139302Updated Dec 1, 2025Results posted

A Study to Test How Different Doses of Nerandomilast (BI 1015550) Are Taken up in the Body of Healthy Japanese Men

A Phase 1 interventional study of Nerandomilast in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Japan. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The main objectives of this trial are to investigate pharmacokinetics (PK) of R-BI 1015550 in Japanese healthy male subjects following oral administration of two different single BI 1015550 doses.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR), Respiratory rate (RR)), 12-lead (ECG), and clinical laboratory tests
  • Age of 18 to 45 years (inclusive)
  • (BMI) of 18.5 to 25 kg/m2 (inclusive)
  • Signed and dated written in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial

Exclusion criteria

Exclusion Criteria:

  • Any finding in the medical examination (including BP, PR, RR or ) deviating from normal and assessed as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre(s) of mercury (mmHg), diastolic blood pressure outside the range of 40 to 90 mmHg, or PR outside the range of 40 to 99 beats per minute (bpm)
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease assessed as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  • History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Nerandomilast 9 mg

    Participants were administered a single film-coated tablet of 9 mg of nerandomilast (Formulation C1), orally with 240 milliliters (mL) of water after an overnight fast of at least 10 hours (h).

    Drug: Nerandomilast

  • Experimental
    Nerandomilast 18 mg

    Participants were administered a single film-coated tablet of 18 mg of nerandomilast (Formulation C1), orally with 240 milliliters (mL) of water after an overnight fast of at least 10 hours (h).

    Drug: Nerandomilast

Interventions

  • Participants were administered a single film-coated tablet of nerandomilast (Formulation C1), orally with 240 milliliters (mL) of water after an overnight fast of at least 10 hours (h).

    Also known as: BI 1015550, JASCAYD®

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)

    Area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) is reported.

    Time frame: Within 3 hours (hrs) before drug intake and at 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 and 144 hrs after drug intake.

  2. Maximum Measured Concentration (Cmax) of Nerandomilast in Plasma

    Maximum measured concentration (Cmax) of nerandomilast in plasma is reported.

    Time frame: Within 3 hours (hrs) before drug intake and at 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 and 144 hrs after drug intake.

07

Results

Posted Dec 1, 2025

Participant flow

This was an open-label, non-randomized, and parallel group design study aimed to investigate pharmacokinetics of R-BI 1015550 (nerandomilast) in healthy Japanese male subjects following oral administrations of a single nerandomilast dose of 9 milligrams (mg) or 18 mg.

Participant flow — Overall Study
MilestoneNerandomilast 9 mgNerandomilast 18 mg
Started66
Completed66
Not completed00

Outcome measures

PrimaryArea Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)

Area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) is reported.

Time frame:
Within 3 hours (hrs) before drug intake and at 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 and 144 hrs after drug intake.
Reported as:
Geometric mean · hours*nanomoles/Liter (h*nmol/L)
Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)
hours*nanomoles/Liter (h*nmol/L)Nerandomilast 9 mgNerandomilast 18 mg
Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)2070 ± 13.83740 ± 52.8
PrimaryMaximum Measured Concentration (Cmax) of Nerandomilast in Plasma

Maximum measured concentration (Cmax) of nerandomilast in plasma is reported.

Time frame:
Within 3 hours (hrs) before drug intake and at 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 and 144 hrs after drug intake.
Reported as:
Geometric mean · nanomoles/Liter (nmol/L)
Maximum Measured Concentration (Cmax) of Nerandomilast in Plasma
nanomoles/Liter (nmol/L)Nerandomilast 9 mgNerandomilast 18 mg
Maximum Measured Concentration (Cmax) of Nerandomilast in Plasma455 ± 10.6628 ± 138

Adverse events

Collected over Serious adverse events, other adverse events and all-cause mortality: From time of trial drug administration up to 7 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nerandomilast 9 mg0/6 (0%)0/6 (0%)1/6 (16.7%)
Nerandomilast 18 mg0/6 (0%)0/6 (0%)0/6 (0%)
Most frequent other events
Most frequent other events
EventNerandomilast 9 mgNerandomilast 18 mg
NasopharyngitisInfections and infestations1/60/6

Baseline characteristics

Treated set (TS): The treated set included all subjects who were treated with at least one dose of trial drug. The treatment assignments were determined based on the first treatment the subjects received. The treated set was used for safety analyses.

Age, Continuous
Age, Continuous(Years)Nerandomilast 9 mgNerandomilast 18 mgTotal
Mean31.8 ± 10.126.2 ± 9.629.0 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Nerandomilast 9 mgNerandomilast 18 mgTotal
Female000
Male6612
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nerandomilast 9 mgNerandomilast 18 mgTotal
Hispanic or Latino000
Not Hispanic or Latino6612
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nerandomilast 9 mgNerandomilast 18 mgTotal
American Indian or Alaska Native000
Asian6612
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • SOUSEIKAI Sumida Hospital
    Tokyo, Sumida-ku, 130-0004, Japan
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Feb 2024, 1 month.

Results were first posted in Dec 2025, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2023
First posted
Nov 18, 2023
StartActual
Dec 20, 2023
Primary completionActual
Feb 7, 2024
CompletionActual
Feb 13, 2024
Results first posted
Dec 1, 2025
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06139302
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Dec 20, 2023
Primary completion
Feb 7, 2024
Completion
Feb 13, 2024
Results posted
Dec 1, 2025
Last update
Dec 1, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion